New-age Technology Capable of Targeted Drug Delivery Thrives

North America is home to the majority of drug delivery innovations, Says Frost & Sullivan

MOUNTAIN VIEW, California, Dec. 16, 2015 /PRNewswire/ -- The drug delivery space presents numerous opportunities for technology advancements, most importantly in the area of scalability. Once drug delivery products start incorporating upscale technologies, manufacturers will naturally focus on application diversity and seek opportunities to license out their technologies to various industries such as medicine, animal health and cosmetics.

Logo - http://photos.prnewswire.com/prnh/20151214/295678LOGO

Analysis from Frost & Sullivan, Advanced Mechanisms in Drug Delivery (http://bit.ly/1YYBGMx), finds hydrogels, phospholipids, microspheres, cyclodextrins and nanotechnology based formulations are emerging drug delivery mechanisms that will displace established technologies such as polymeric micelles, niosomes, phosphorous acids and starch-based structures. Not only are these new-age drug delivery mechanisms biodegradable and non-toxic, they also enhance the bioavailability of drugs, promote solubility in various environments and ensure targeted delivery.

For complimentary access to more information on this research, please visit: http://bit.ly/1OQyqA3.

"The targeted drug delivery mechanism successfully challenges traditional drug delivery technologies that have to pass through the gastrointestinal tract to reach the disease site," said TechVision Research Analyst Karan Verma. "Besides their precision, the emerging targeted drug delivery technologies are noted for their high lipophilicity, which enhances the entrapment efficiency of drugs."

While companies can succeed in bringing healthcare providers on board with the practice of targeted drug delivery, they will find it more challenging to convince end users to abandon their trusted traditional solutions.

"As things stand, the North American market accounts for the majority of innovations in the global drug delivery industry. Unsurprisingly, the majority of drug delivery technology manufacturers are based in the U.S., closely followed by Europe," noted Verma. "However, since Asia-Pacific is the fastest-growing market in terms of the demand for oral drugs for infectious diseases, it too is an important region for the drug delivery technology industry."

Moreover, these new drug delivery technologies will allow industry players to create a streamlined financial path. For manufacturers across geographies, partnerships and alliances will be essential to sustaining costs associated with R&D and the commercialization of products currently under regulatory review. Venture capital funding, angel investors and series funding also represent possible sources of financial support for product development.

Advanced Mechanisms in Drug Delivery, a part of the TechVision (http://ww2.frost.com/research/technology/health-wellness) subscription, provides a detailed description of emerging drug delivery mechanisms that could disrupt existing technologies. The study also covers drivers and challenges for individual drug delivery mechanisms, and each technology's year of impact on the healthcare space. Additionally, the study includes a comprehensive stakeholder analysis, a SWOT analysis of current companies to highlight opportunities for prospective firms, major partnerships in the drug delivery market and strategies that will help players grow their business exponentially.

Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including research, analysis, strategy, vision, innovation and implementation.
• The Partnership Infrastructure is unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Advanced Mechanisms in Drug Delivery
D6A0

Contact:
Kayla Belcher
Corporate Communications – North America
P: 210.247.2450
F: 210.348.1003
E: kayla.belcher@frost.com

http://www.frost.com
http://www.frost.com/techvision

Related Links

http://www.frost.com